phospholipase A2 inhibitor and LY6/PLAUR domain containingGenealiases: []
Q-omics provides the consensus-scored PINLYP profile across patient tissues and cancer cell-line models. PINLYP expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, PINLYP is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PINLYP RNA expression shows 14,148 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, KIRC, and TGCT as cancer lineages where PINLYP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PINLYP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PINLYP survival associations across molecular data types. PINLYP RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PINLYP RNA expression–survival associations across cancer types. High PINLYP expression shows unfavorable associations in LGG, STAD and ACC, but favorable associations in HNSC, LUAD and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for PINLYP RNA expression.
This table summarizes PINLYP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PINLYP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PINLYP shows lower tumor expression in KIRC, KIRP, STAD, LUAD, UCEC and BLCA. The KIRC box plot shows higher PINLYP RNA expression in normal versus tumor tissue (log2 FC = −1.485, t-test p < 0.001).
This table shows molecular features associated with PINLYP in patient tissues and cancer cell lines. In patient samples, PINLYP shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PINLYP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LUNG_SCLC.
